SCM
XENE icon

Silverarc Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Silverarc Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
186,821
-10,938
-6% -$607K 1.17% 29
2026
Q1 		$11.5M Buy
+197,759
New +$9.11M 1.17% 24
2025
Q2 		– Sell
-10,121
Closed -$340K – 88
2025
Q1 		$340K Buy
+10,121
New +$384K 0.07% 65
2024
Q2 		– Sell
-66,090
Closed -$2.85M – 89
2024
Q1 		$2.85M Sell
66,090
-97,078
-59% -$4.47M 0.79% 38
2023
Q4 		$7.52M Buy
163,168
+109,172
+202% +$3.86M 2.24% 16
2023
Q3 		$1.84M Sell
53,996
-45,760
-46% -$1.71M 0.56% 48
2023
Q2 		$3.84M Buy
99,756
+3,113
+3% +$124K 1.19% 29
2023
Q1 		$3.46M Sell
96,643
-157,012
-62% -$5.8M 1.43% 27
2022
Q4 		$10M Buy
253,655
+7,663
+3% +$279K 2.86% 6
2022
Q3 		$8.88M Buy
245,992
+13,362
+6% +$480K 3% 10
2022
Q2 		$7.08M Buy
232,630
+131,549
+130% +$3.98M 2.18% 16
2022
Q1 		$1.43M Buy
101,081
+1,081
+1% +$32.4K 0.59% 43
2021
Q4 		$3.12M Buy
100,000
+80,568
+415% +$2.41M 1.27% 27
2021
Q3 		$297K Buy
+19,432
New +$338K 0.17% 77

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Silverarc Capital Management's XENE Position: Q2 2026 in Review

Silverarc Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 5.5% in Q2 2026, selling an estimated $607K and leaving 186,821 shares worth $11.3M. The position accounts for 1.17% of the portfolio, ranked #29.

Silverarc Capital Management first reported a position in XENE in Q3 2021 and has held it in 14 quarters since. The position peaked at $11.5M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Silverarc Capital Management held 186,821 shares of Xenon Pharmaceuticals worth $11.3M as of Q2 2026.
  • Silverarc Capital Management sold 10,938 Xenon Pharmaceuticals shares in Q2 2026, an estimated $607K.
  • Xenon Pharmaceuticals made up 1.17% of Silverarc Capital Management's portfolio in Q2 2026, its #29 holding.
  • Silverarc Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
  • Silverarc Capital Management's Xenon Pharmaceuticals position peaked at $11.5M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.